New SPINRAZA® (NUSINERSEN) SOCIETY DEMONSTRATE BENEFITS IN TREATING PRESYMPTOMATIC INFANTS WITH SPINAL MUSCULAR ATROPHY
CAMBRIDGE, Mass., Oct. 06, 2018 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new interim results from NURTURE, an ongoing open-label, single-arm efficacy and safety study of SPINRAZA® (nusinersen) in 25 presymptomatic infants with SMA. The data are being presented today in a late-breaking session at the 23rd Annual Congress of the World Muscle Society (WMS) held in Mendoza, Argentina.
“The NURTURE study results demonstrate that early diagnosis and treatment with SPINRAZA has the potential to dramatically change the course of SMA,” said Wildon Farwell, M.D., senior medical director, clinical development at Biogen. “This is the longest available span of data on infants with SMA who began treatment in a presymptomatic period and indicates that children treated early with SPINRAZA can achieve motor milestones they would likely not attain without treatment.”
More Details see below